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Bronchodilators are widely used in Cystic Fibrosis (CF), due to hyperreactivity
secondary to bronchial damage and/or atopy. They improve sintomatology and
prevent bronchoconstriction associated with treatments. Many show acute improve-
ment of FEV1 following b-agonist administration, but response varies over time. A
sub-group has acute airways obstruction reversible by b-agonists and atopy, often
revealed by increased IgE. These patients may beneﬁt more from bronchodilators
chronic use.
Aims: To determine the prevalence of bronchodilation responsiveness and its
association with IgE in CF pediatric patients.
Methods: Retrospective study of all patients over 5 years-old followed in our CF
Center during 2008 that had 2 lung function tests (LFT) and IgE determination.
Data collected included: demographics, IgE and LFT with bronchodilation test using
inhaled salbutamol. An increase in FEV110% was considered signiﬁcative.
Results: 35 patients fulﬁlled the inclusion criteria. The median age was
13 years(±4.2). Global severety of lung disease was mild (FEV1 76.2±27.7%). Pos-
itive bronchodilation test was found in 34.2% and 11.4% mantained responsiveness
in 2 LFT. 42.9% patients had increased IgE, 40% of whom had bronchodilation.
There was no association between increased IgE and responsiveness. Patients with
bronchodilation responsiveness had lower FEV1 (74.9% vs 77%; p> 0.05) as did
those with increased IgE (72.6% vs 78.9%; p> 0.05).
Discussion: In our study many patients had bronchodilator responsiveness, though
few showed consistent response over time. Increased IgE prevalence was high. Both
bronchodilation and increased IgE were associated with lower FEV1. Studies are
needed to determine the real beneﬁts of b-agonists use in the long term in patients
with and without atopy.
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Bronchiolitis obliterans (BO) is a mayor cause of death after lung and stem cell
transplantation being treated today with systemic immunosuppressive drugs, e.g.
Ciclosporin A (CsA). Since systemic CsA is of limited efﬁcacy to prevent or treat
BO and it also has severe nephrotoxic effects direct intrapulmonary CsA delivery
may result in higher local drug exposure and better effect in association with less
systemic side effects. Reports on positive therapeutic effects upon nebulisation
of CsA (Iacono et al. 2006) dissolved in propylenglycol (CsA-PG) indicated that
inhaled CsA may be advantageous. Still treatment compliance to inhaled CsA was
poor due to the irritating organic solvent and long nebulisation times up to 1 hour.
A well tolerable inhalation formulation in a low, non toxic dose with short delivery
times was the target. A novel aqueous liposomal CsA (L-CsA) formulation showed
good cell tolerability in a Calu-3 epithelial cell culture model and was non toxic in
rats when inhaled for 6 months. Lung deposition in 12 lung transplanted patients
was about 40% after inhalation of 10mg L-CsA via a customised eFlow® electronic
nebuliser and 50% were found in the lung periphery (Behr et al. 2007). Compared
to CsA-PG a sustained release could be observed for L-CsA after incubation of
human lung cell homogenates (Trammer et al. 2008). In a perfuse rabbit lung model,
highest drug distribution was found after 6 h in homogenates (78%), perfusate (6%)
and lavage (16%) (Leuchte et al. submitted). A soon starting phase II program may
prove the efﬁcacy and safety of inhaled L-CsA delivered via a customised eFlow®
electronic nebuliser.
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A modiﬁed scoring system based on chest MRI was designed to objectively grade
the severity and extention of lung disease in CF. 15 patients with CF underwent
chest morphological MRI. Functional MR ventilation was also assessed by using
dedicated Oxigen-related sequences. All patients also underwent a HRCT within
7 days.MRI was scored using a modiﬁed Baumann-CT scoring system.MRI score
of each patient was calculated on the basis of bronchiectasis and divided into 4
score-group. Extra-ﬁndings such as: air trapping, ventilation defects, micetoma and
pancreatic changes were also recorded.A good morphological correlation was found
between 2 radiologists to evaluate mucus plugging and atelectasis, even in patients
with a low grade of the disease. All MRI ﬁndings were also conﬁrmed by CT
with a very high agreement between the 2 radiologists and both the techniques.
Fungal infection was found in 3 patients.MRI showed in these patients a better
delineation of the central cavitation of the micetoma as compared to HRCT. Severe
air trapping was found by CT in 4 patients. In 3 of these it was recognized also by
MRI whom also showed focal and segmental defects when pure O2 was inhaled.
Sensitivity, speciﬁcity and accuracy for the scoring system were respectively 99%,
96% and 97% for MRI, compared to CT. A complete agreement was reached
for bronchiectasis. MRI might be a feasible and not invasive diagnostic imaging
technique to stage pediatric patients with cystic ﬁbrosis avoiding exposure toXR.
Further studies will able to conﬁrm and improve our results.
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The severity of chronic bronchopulmonary inﬂammation is the limited factor for
surviving of CF patients. Novel therapies (inhaled antibiotics, rhDNAse, respiratory
physiotherapy) and multidisciplinary approach results to rising median surviving age
and better QoL as well. Lung function testing is an important marker of lung im-
pairment, but it seems to be less sensitive in comparison to HRCT of lung in CF. In
previous study (Belfast, 2003) we concluded that HRCT was more sensitive method
of evaluating pathologic changes in CF lung (mucus plugging, thickening of airway
wall, bronchiectasiones, inﬂammatory process, air-trapping, emphysema) than LFT,
which could be in normal ranges in patients with advanced CF disease. According
to localisation and type of changes we can start with segmental physiotherapy, more
intensive mucolytic therapy (rhDNA), anti-inﬂammatory therapy.
Aims: To evaluate the changes of lung function (LFT) and morphologic changes
in HRCT in 8 years period and correlate them with genotype and clinical status of
patients.
Methods: We examinated 116 CF pts with more than 3 HRCT (every 2 yeras)
examinations done from the year 2000.
Results: 79 pts with severe CFTR mutations (mean age: 18.8 years, FVC: 86.4%,
FEV1: 83.7%, MEF50: 69.9%). Staging according Bhalla: 6.97 for right lobe, 6.71
for left lobe. 37 pts with mild CFTR mutations with normal LFT (FVC: 89.4%,
FEV1: 89.3%, MEF50: 80.3%), but signiﬁcantly lower HRCT score (RL: 2.97,
LL: 2.53).
Conclusion: Mean HRCT score and LFT did not change in most CF patients with
intensive standard therapy in this time period. HRCT score correlates with CFTR
genotype and compliance with therapy.
